secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0000950170-24-136408
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen appoints David DeLucia as CFO effective Dec 16, 2024
-------------------------------------------------------------

- David DeLucia, previously VP of FP&A and IR, promoted to CFO, succeeding Juan Graham who stepped down Dec 15.
- DeLucia has nearly 15 years life sciences finance experience; previously at TherapeuticsMD and JP Morgan Asset Mgmt.
- As CFO, DeLucia will oversee finance, treasury, IR; reports to CEO Thane Wettig.
- Severance terms include 9 months salary for ordinary termination; 12 months salary plus bonus & equity vesting for CIC termination.
- Company highlights advancing FG-3246 ADC and companion diagnostic FG-3180 alongside roxadustat performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024136408/0000950170-24-136408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024136408/fgen-20241216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-136408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer